Optimizing Treatment for Patients with Relapsed/Refractory Multiple Myeloma

home / around-the-practice / optimizing-treatment-for-patients-with-relapsed-refractory-multiple-myeloma

Following the 2024 ASCO Annual Meeting, a panel of experts on multiple myeloma review recent updates and discuss evolving treatment practices.

A panel of 4 experts on multiple myeloma

EP. 1: Advancements in the Treatment of Newly Diagnosed MM: Updates from the Phase 3 IMROZ Study

Rafael Fonseca, MD;Samer A. Al'Hadidi, MD;Naresh Bumma, MD;Hans Lee, MD
June 28th 2024

A panel of experts on multiple myeloma introduce themselves and discuss recent data presented on the phase 3 IMROZ trial for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).

A panel of 4 experts on multiple myeloma

EP. 2: Navigating Treatment Advancements and Recent Approvals in R/R Multiple Myeloma: Expert Insights

Rafael Fonseca, MD;Samer A. Al'Hadidi, MD;Naresh Bumma, MD;Hans Lee, MD
June 28th 2024

Focusing on recent approvals in earlier lines of relapsed/refractory multiple myeloma, the panel has a comprehensive discussion on the CARTITUDE-4 and KarMMa-3 studies and shares clinical insights on administering CAR T-cell therapy and monitoring patients.

A panel of 4 experts on multiple myeloma

EP. 3: Updates From the Phase 2 MonumenTAL-2 Study Investigating Talquetamab in R/R MM

Rafael Fonseca, MD;Samer A. Al'Hadidi, MD;Naresh Bumma, MD;Hans Lee, MD
July 5th 2024

Hans Lee, MD, discusses recent updates from the MonumenTAL-2 study investigating talquetamab in patients with relapsed/refractory multiple myeloma.

A panel of 4 experts on multiple myeloma

EP. 4: Long-Term Follow-up with Teclistamab in R/R MM: Updates from MajesTEC-1

Rafael Fonseca, MD;Samer A. Al'Hadidi, MD;Naresh Bumma, MD;Hans Lee, MD
July 5th 2024

Samer Al'Hadidi, MD, provides an overview of recent updates presented at ASCO 2024 from the MajesTEC-1 trial evaluating teclistamab in patients with relapsed/refractory multiple myeloma.